Articles tagged with Prostate Cancer
A recent study shows that a PET/CT scan using F-18-DCFBC is significantly more effective in detecting metastatic prostate cancer than other detection methods. The radiotracer targets prostate-specific membrane antigen, which is expressed in the majority of prostate cancers and associated with metastatic spread.
A study found that 15.7% of individuals 65 or older received nonrecommended screenings for prostate and breast cancers due to limited life expectancy, costing the US healthcare system $1.2 billion annually. States with high rates of nonrecommended screening showed similar patterns in both prostate and breast cancer screenings.
A new study reveals that docetaxel retains effectiveness in patients with castration-resistant metastatic prostate cancer (mCRPC) treated with abiraterone. Following abiraterone, 40% of patients experienced a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of this drug sequencing.
A recent study published in The Journal of Urology found that reduced prostate needle biopsies are associated with a higher risk of being diagnosed with high-risk disease. This could lead to delayed diagnosis and potentially avoidable cancer deaths. The study's findings highlight the need for balanced screening approaches and more effe...
A new study led by Sheffield Hallam University is exploring the potential of exercise as a treatment for prostate cancer. The PANTERA study involves 50 men with non-spreading cancer, who will either undergo supervised exercise sessions or receive information on exercise benefits but no sessions.*
A new study found that African American men with low-grade prostate cancer produce less PSA and have significantly lower PSA density than Caucasian men. This could lead to inaccurate surveillance criteria and affect treatment decisions for African American patients.
Researchers have found that screening male kidney transplant candidates for prostate cancer does not prolong their survival and may even delay receiving a transplant. Elevated PSA levels detected through screening were associated with a reduced likelihood of receiving a transplant regardless of the patient's age or PSA level.
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
Researchers discovered an unexpected link between two common prostate cancer treatments, radiation and androgen ablation. This connection allows doctors to better determine which treatment will benefit individual patients, potentially leading to improved prostate cancer treatments.
A meta-analysis of 19 studies involving over 118,000 patients found that surgery resulted in lower mortality rates compared to radiation treatment. Patients treated with surgery were twice as likely to survive prostate cancer than those treated with radiation.
Researchers at Houston Methodist Hospital developed a suicide gene therapy that combines radiation treatment with a genetically modified virus to target and destroy cancer cells. The treatment shows high five-year overall survival rates of 97% and 94%, improving upon historical studies by 5-20%.
A recent study found that PET/CT and whole-body MRI detect extraskeletal disease, changing cancer management. Combined administration of F-18 sodium fluoride (NaF) and F-18 fluorodeoxyglucose (FDG) in a single PET/CT scan showed higher sensitivity and accuracy than alternative methods.
A new study from The Ottawa Hospital and the University of Ottawa found that repeating an abnormal PSA test reduces unnecessary biopsies by 55 percent. Men with conflicting test results who had a second normal test were diagnosed with cancer within a year, suggesting the importance of repeat testing.
A Stanford University study has found that men treated with androgen deprivation therapy for prostate cancer are nearly twice as likely to be diagnosed with Alzheimer's disease. The researchers analyzed electronic medical records of thousands of patients, revealing a significant increase in cognitive decline among those receiving ADT.
A new study published in Annals of Oncology shows that abiraterone acetate is effective in treating aggressive prostate cancers, even those with high Gleason scores. The treatment extended progression-free survival by up to 16.5 months in patients previously treated with docetaxel.
A UCLA study found that less than 5% of men with low-risk prostate cancer undergoing active surveillance receive regular monitoring, putting them at risk of cancer progression. The study suggests that patients and doctors should agree on a follow-up schedule to closely monitor the cancer.
A new drug combination is being tested for its effectiveness in treating metastatic prostate cancer. Researchers are optimistic about the results, citing improved quality of life and delayed disease progression in patients participating in a Phase 3 clinical trial.
Researchers found that a secreted bone protein called Sclerostin inhibits prostate cancer metastasis to bone. The study also showed that lack of SOST in the bone microenvironment promotes expression of genes associated with cell migration and invasion.
Two studies found a decline in early-stage prostate cancer incidence and PSA-based screening rates among men 50 years and older following the 2012 USPSTF screening recommendations. The decline was most pronounced in younger men, with significant reductions in PSA screening rates observed between 2010 and 2013.
PSA testing has declined dramatically in middle-aged men after a 2012 recommendation against routine screening, according to a new study. The biggest declines were seen in men ages 50-54 and 60-64 years old.
Men with prostate cancer who undergo radiation therapy can benefit from yoga, which stabilizes fatigue, sexual health, and urinary incontinence. Yoga also improves general quality of life by reducing cancer-related fatigue and strengthening pelvic floor muscles.
A new blood test for prostate cancer significantly improves detection of aggressive cancer, reducing false positives and unnecessary biopsies. The STHLM3 test analyzes protein markers, genetic data, and clinical information to detect cancers in men with low PSA values.
A new study by UCLA researchers reveals a wide range of costs for treating low-risk prostate cancer, with active surveillance being the most cost-effective option. The study used time-driven activity-based costing to analyze costs across an entire care process, finding significant variation in prices for different treatments.
A new clinical trial has shown that a gene-targeted drug, olaparib, can benefit up to 33% of patients with treatment-resistant advanced prostate cancer. The trial found that men whose tumours had defects in DNA repair machinery responded particularly well to the drug.
A new genetic discovery has identified a significant gene called miR137 that is switched off in prostate cancer cells, contributing to the disease's initiation and progression. The study also identified potential targets for next-generation drugs to treat prostate cancer.
Black men with localized prostate cancer had poorer quality care, higher costs, and worse postoperative outcomes compared to white men. However, the authors found no difference in cancer-specific or overall death between the two groups.
The RTOG 9601 study found that adding anti-androgen therapy to salvage radiotherapy improved overall survival and reduced prostate cancer death. The treatment also showed no significant increase in radiation toxicity.
Primary care providers should screen men aged 45 and older with a digital rectal exam (DRE) and prostate-specific antigen (PSA) test. If the patient is asymptomatic, a 5-year screening interval may be considered.
Researchers identified a key mechanism driving prostate cancer development, where normal cells undergo epigenetic reprogramming to form malignant growth. The study provides insights into the origins of prostate cancer and potential targets for prevention and treatment.
Researchers presented various applications of Bio-Rad's Droplet Digital PCR, including copy number determination, genome editing, and liquid biopsy. The technology demonstrated precision, reproducibility, and sensitivity in detecting complex genomic rearrangements and biomarker levels.
A new population-based study found no association between testosterone therapy and aggressive prostate cancer risk over a five-year period. The study analyzed data from Medicare linked records and included 52,579 men diagnosed with prostate cancer between 2001-2006.
The new guidelines promise to improve the detection of life-threatening tumors and reduce unnecessary biopsies, with the potential to save lives. The standards for acquiring and reporting MRI scans will be widely adopted, making it easier for doctors to identify significant cancers.
Researchers are investigating two new avenues for detection and treatment of advanced prostate cancer, focusing on biochemical reactions downstream of the androgen receptor. By targeting the metabolism of cancer cells, they aim to bypass ineffective drugs and develop new therapies.
New research analyzed data from the US Nationwide Inpatient Sample to identify prostate cancer risk factors. The study found that age, race, and family history are significant risk factors for prostate cancer, while obesity, alcohol abuse, and smoking show a protective effect.
A new trial has shown that giving patients fewer but higher doses of radiotherapy is as effective in treating prostate cancer as longer treatment periods. The study found that this approach resulted in fewer side effects and reduced the need for hospital visits, potentially saving over 150,000 trips per year.
A recent study found that reduced prostate specific antigen (PSA) screening led to a decline in intermediate and high-risk prostate cancer diagnoses by 28% over a year. However, this reduction also resulted in delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators.
A long-term follow-up study found that men with comorbidity and a prior heart attack who received androgen deprivation therapy had a higher risk of fatal heart attacks. The study suggests that treatment with radiation therapy alone may be a safer option for these patients.
A study suggests that radiation therapy alone is associated with decreased overall and cardiac mortality in men with unfavorable-risk prostate cancer and moderate or severe comorbidity. In contrast, the combination of radiation therapy and androgen deprivation therapy may not provide additional benefits for these patients.
Active surveillance can reduce overtreatment by almost 50 percent at 15 years, according to a new review article. The approach involves monitoring and testing patients with regular intervals, rather than immediate treatment. The authors found that this strategy can balance the risk of overdiagnosis and overtreatment in prostate cancer.
A new imaging agent, Ga-68 PSMA, significantly improved detection of early recurrent prostate cancer in a study published in The Journal of Nuclear Medicine. The agent was found to detect sites of possible recurrence in 50% of patients with low PSA levels, compared to only 12.5% for another widely used agent.
Researchers at Johns Hopkins Medicine analyzed survival statistics of 1,298 men with low-risk prostate tumors and found that only two died of prostate cancer after 15 years, while three developed metastatic disease. This suggests that carefully selected patients in active surveillance programs are unlikely to be harmed by their disease.
Researchers developed a molecular imaging biomarker that detects fast-growing primary prostate cancer and distinguishes it from benign prostate lesions. The new PSMA-based PET imaging technique was more specific than MR imaging for detecting clinically significant high-grade prostate cancer lesions.
Black men in England face a double lifetime risk of being diagnosed with and dying from prostate cancer compared to their white counterparts. The study reveals that Asian men have half the lifetime risk, highlighting the need for targeted awareness-raising and informed decision-making about PSA tests.
A new study using human embryonic stem cells suggests that early exposure to bisphenol A may lead to an increased risk of prostate cancer. The research found that BPA caused the development of prostate organoids to produce an overabundance of prostate stem cells, which could be a risk factor for cancer.
Researchers have identified five distinct types of prostate cancer with unique genetic fingerprints, which could help doctors predict the aggressiveness of tumors and choose the best course of treatment. This breakthrough discovery has important implications for how prostate cancer is diagnosed and treated in the future.
University of York scientists identified how tiny regulatory molecules in cells make prostate cancers resistant to radiotherapy. By manipulating these critical micro-RNAs, it may be possible to kill more cancer stem cells and extend the lives of thousands of men.
Researchers found that men with low-risk prostate cancer are increasingly opting for active surveillance, while those with higher-risk tumors are receiving more aggressive treatments. This shift aims to reduce overtreatment and improve outcomes for patients.
Researchers identified a subset of genes known as biomarkers that define a genomic subtype of prostate cancer more common in African American men. This subtype signals a more aggressive disease and is defined by the absence or low levels of three genes: ERG, ETS, and SPINK1.
A new study found that increased radiation dose offers no survival benefit for patients with low-risk prostate cancer. In contrast, men with medium- and high-risk cancers saw improved survival rates with higher doses.
Researchers at Thomas Jefferson University discovered DNA-PKcs as a central regulator of metastatic processes in prostate cancer. The kinase modulates signaling networks that turn on metastatic processes, and its levels can predict poor outcomes in patients. A potential drug inhibitor, CC-115, is currently being tested in clinical trials.
Rates of active surveillance for low-risk prostate cancer increased sharply from 2010 to 2013, while high-risk disease was treated more appropriately with local treatments. Treatment patterns varied across individual practices, but suggest a genuine change in prostate cancer management in the US.
Researchers developed a smart sensor chip that can detect subtle differences in glycoprotein molecules, improving prostate cancer diagnosis accuracy and reducing false positives. The technology focuses on the carbohydrate part of the molecule, which is essential for detecting disease.
A UCLA review of common practices in prostate cancer has found that monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance is an effective approach for many patients. This approach could spare them the debilitating side effects of aggressive treatments, which are often used unnecessari...
RIT professor Hans Schmitthenner is designing molecular imaging compounds that selectively target prostate cancer cells, using contrast dyes for improved detection. The preclinical phase project aims to enhance image-directed biopsies, potentially reducing pain and side effects.
A small molecule agent PSMA-617 specifically attaches to prostate-specific membrane antigen on cancer cells, allowing for early detection of secondary tumors and monitoring response to therapy. This agent has shown promising results in PET scans and holds potential as a therapeutic option for hormone-resistant prostate carcinoma.
A Vanderbilt-led study found a 28% decline in new prostate cancer diagnoses in the U.S. following the USPSTF's recommendation to discontinue routine PSA screenings. This decrease was observed mainly among low-risk cancers and men over age 70.
A new blood test has been developed to identify men with a genetically inherited risk of developing prostate cancer. The test analyzes DNA variants associated with increased risk and has shown promise in identifying high-risk individuals.
A small clinical trial found that men with advanced prostate cancer and the AR-V7 gene variant respond to chemotherapy just as well as those without the variant. The study's findings may lead to improved treatment decision-making for patients with prostate cancer.
A new molecular imaging agent has been developed to detect prostate cancer that has spread to other tissues. The agent targets the PSMA enzyme, which is associated with prostate cancer, and has shown high accuracy in detecting disease sites, including those not identified by conventional methods.
Researchers developed PSMA-617, a theranostic drug that detects prostate cancer and targets enzyme on cancer cells. The technology shows substantial reduction in radiotracer uptake and significant decrease in PSMA in blood after therapy, indicating positive response.